These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 9800932)

  • 1. An audit of anti-D sensitisation in Yorkshire.
    McSweeney E; Kirkham J; Vinall P; Flanagan P
    Br J Obstet Gynaecol; 1998 Oct; 105(10):1091-4. PubMed ID: 9800932
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted routine antenatal anti-D prophylaxis in the prevention of RhD immunisation--outcome of a new antenatal screening and prevention program.
    Tiblad E; Taune Wikman A; Ajne G; Blanck A; Jansson Y; Karlsson A; Nordlander E; Holländer BS; Westgren M
    PLoS One; 2013; 8(8):e70984. PubMed ID: 23940682
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The scientific basis of antenatal prophylaxis.
    Urbaniak SJ
    Br J Obstet Gynaecol; 1998 Nov; 105 Suppl 18():11-8. PubMed ID: 9863973
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and long term effects of antenatal prophylaxis with anti-D immunoglobulin.
    Thornton JG; Page C; Foote G; Arthur GR; Tovey LA; Scott JS
    BMJ; 1989 Jun; 298(6689):1671-3. PubMed ID: 2547468
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A review of maternal alloimmunisation to Rh D in Northern Ireland.
    McCauley CJ; Morris K; Maguire K
    Transfus Med; 2017 Apr; 27(2):132-135. PubMed ID: 28101958
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An audit of the investigation and use of anti-D immunoglobulin prophylaxis in Tayside.
    Rennie I; Smith A; Smith R; Rawlinson PS; Clark P
    Health Bull (Edinb); 2001 May; 59(3):150-4. PubMed ID: 12664753
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk factors for RhD immunisation despite antenatal and postnatal anti-D prophylaxis.
    Koelewijn JM; de Haas M; Vrijkotte TG; van der Schoot CE; Bonsel GJ
    BJOG; 2009 Sep; 116(10):1307-14. PubMed ID: 19538414
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted antenatal anti-D prophylaxis program for RhD-negative pregnant women - outcome of the first two years of a national program in Finland.
    Haimila K; Sulin K; Kuosmanen M; Sareneva I; Korhonen A; Natunen S; Tuimala J; Sainio S
    Acta Obstet Gynecol Scand; 2017 Oct; 96(10):1228-1233. PubMed ID: 28718198
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Guideline for prevention of RhD alloimmunizationin RhD negative women].
    Lubušký M; Procházka M; Simetka O; Holusková I
    Ceska Gynekol; 2013 Apr; 78(2):132-3. PubMed ID: 23710977
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Implementation of the rhesus prevention programme: a prospective study.
    Ghosh S; Murphy WG
    Scott Med J; 1994 Oct; 39(5):147-9. PubMed ID: 8778974
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Foetal Rhesus-D typing added to antenatal screening for infectious diseases and erythrocyte immunisation].
    van der Ploeg CP; Hirschberg HJ; de Haas M; Abbink F
    Ned Tijdschr Geneeskd; 2015; 159():A8315. PubMed ID: 25898866
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Spontaneous antepartal RhD alloimmunization].
    Studničková M; Holusková I; Durdová V; Kratochvílová T; Strašilová P; Marková I; Lubušký M
    Ceska Gynekol; 2015 Dec; 80(6):401-4. PubMed ID: 26741153
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Routine antenatal Rhesus D immunoglobulin prophylaxis: the results of a prospective 10 year study.
    MacKenzie IZ; Bowell P; Gregory H; Pratt G; Guest C; Entwistle CC
    Br J Obstet Gynaecol; 1999 May; 106(5):492-7. PubMed ID: 10430201
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk factors for RhD immunisation in a high coverage prevention programme of antenatal and postnatal RhIg: a nationwide cohort study.
    Slootweg YM; Zwiers C; Koelewijn JM; van der Schoot E; Oepkes D; van Kamp IL; de Haas M
    BJOG; 2022 Sep; 129(10):1721-1730. PubMed ID: 35133072
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Routine antenatal anti-D prophylaxis for RhD-negative women: a systematic review and economic evaluation.
    Pilgrim H; Lloyd-Jones M; Rees A
    Health Technol Assess; 2009 Feb; 13(10):iii, ix-xi, 1-103. PubMed ID: 19210896
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Guideline for prevention of RhD alloimmunization in RhD negative women].
    Lubuský M; Procházka M; Simetka O; Holusková I
    Ceska Gynekol; 2010 Aug; 75(4):323-4. PubMed ID: 20925231
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Following targeted routine antenatal anti-D prophylaxis, almost half of the pregnant women had undetectable anti-D prophylaxis at delivery.
    Sørensen K; Stjern HE; Karlsen BAG; Tomter G; Ystad I; Herud I; Baevre MS; Llohn AH; Akkök ÇA
    Acta Obstet Gynecol Scand; 2022 Apr; 101(4):431-440. PubMed ID: 35224728
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Routine antenatal anti-D prophylaxis and patient compliance with the two-dose regimen.
    Chaffe B; Ford J; Bills V
    Transfus Med; 2007 Oct; 17(5):399-403. PubMed ID: 17903141
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rhesus D alloimmunization in pregnancy from 1996 to 2015 in Iceland: a nation-wide population study prior to routine antenatal anti-D prophylaxis.
    Gudlaugsson B; Hjartardottir H; Svansdottir G; Gudmundsdottir G; Kjartansson S; Jonsson T; Gudmundsson S; Halldorsdottir AM
    Transfusion; 2020 Jan; 60(1):175-183. PubMed ID: 31850521
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Time points and risk factors for RhD immunizations after the implementation of targeted routine antenatal anti-D prophylaxis: A retrospective nationwide cohort study.
    Jernman R; Isaksson C; Haimila K; Kuosmanen M; Mäkikallio-Anttila K; Toivonen S; Ordén MR; Sulin K; Tihtonen K; Vääräsmäki M; Sainio S
    Acta Obstet Gynecol Scand; 2021 Oct; 100(10):1868-1875. PubMed ID: 34157128
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.